Adenovirus-mediated p53 Gene Therapy for Human Gliomas

Adenovirus-mediated p53 Gene Therapy for Human Gliomas AbstractOBJECTIVE:The rationale and current evidence for using p53 gene replacement as a potential treatment for human gliomas are reviewed. The possible benefits of and obstacles to this approach are delineated.METHODS:One approach to overcoming the poor outcomes associated with conventional glioma therapies involves the replacement of tumor suppressor genes that are fundamental to glioma development. The p53 gene is one of the most frequently mutated genes in human gliomas, and loss of p53 function is critical to the development of glial neoplasms. Consequently, replacement of the p53 gene using viral vectors may be a potential treatment for human gliomasRESULTS:In vitro studies demonstrate that adenovirus-mediated p53 gene transfer into gliomas with mutant p53 results in massive apoptosis. Similarly, transfer of p53 inhibits tumor growth in vivo. In contrast to mutant p53 gliomas, wild-type p53 glioma cells are resistant to the apoptotic effects of p53 transfer, but this resistance can be overcome by the addition of deoxyribonucleic acid-damaging agents such as ionizing radiation or chemotherapy. The main obstacle to p53 gene therapy involves the limitations associated with current modes of deliveryCONCLUSION:Preclinical data strongly support the use of p53 gene transfer as a potential treatment for human gliomas. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Adenovirus-mediated p53 Gene Therapy for Human Gliomas

Adenovirus-mediated p53 Gene Therapy for Human Gliomas

F r e d e r i c k F . L a n g , M . D . , W . K . A l f r e d Y u n g , M . D . , R a y m o n d S a w a y a , M . D . , P h i l i p J . T o f i l o n , P h . D . D e p a r t m e n t s o f N e u r o s u r g e r y (FFL, RS, PJT), N e u r o - O n c o l o g y (WKAY), a n d E x p e r i m e n t a l R a d i a t i o n O n c o l o g y (PJT) a n d t h e Brain T u m o r C e n t e r (FFL, W K A Y , RS, PJT), U n i v e r s i t y o f T e x a s , M . D . A n d e r s o n C a n c e r C e n t e r , H o u s t o n , T e x a s OBJECTIVE: The rationale and current evidence for using p 5 3 gene replacement as a potential treatment for human gliomas are reviewed. The possible benefits of and obstacles to this approach are delineated. METHODS: One approach to overcoming the poor outcomes associated with conventional glioma therapies involves the replacement of tumor suppressor genes that are fundamental to glioma development. The p 5 3 gene is one of the most frequently mutated genes in human gliomas, and loss of p53 function is critical to the development of glial neoplasms. Consequently, replacement of the p 5 3 gene using viral vectors may be a potential treatment for human gliomas. RESULTS: In vitro studies demonstrate that adenovirus-mediated p 5 3 gene transfer into gliomas with mutant p 5 3 results in massive apoptosis. Similarly, transfer of p 5 3 inhibits tumor growth in vivo. In contrast to mutant p 5 3 gliomas, wild-type p 5 3 glioma cells are resistant to the apoptotic effects of p 5 3 transfer, but this resistance can be overcome by the addition of deoxyribonucleic acid-damaging agents such as ionizing radiation or chemotherapy. The main obstacle to p 5 3 gene therapy involves the limitations associated with current modes of delivery. CONCLUSION: Preclinical data strongly support the use of p 5 3 gene transfer as a potential treatment for human gliomas. (Neurosurgery 45:1093-1 104, 1999) Keywords: Apoptosis, G e n e therapy, Gliomas, p 5 3 gene l a t o r s ( M d m - 2 ) h a...
Loading next page...
 
/lp/ou_press/adenovirus-mediated-p53-gene-therapy-for-human-gliomas-xnZZcXNeGj
Publisher
Congress of Neurological Surgeons
Copyright
© Published by Oxford University Press.
ISSN
0148-396X
eISSN
1524-4040
D.O.I.
10.1097/00006123-199911000-00016
Publisher site
See Article on Publisher Site

Abstract

AbstractOBJECTIVE:The rationale and current evidence for using p53 gene replacement as a potential treatment for human gliomas are reviewed. The possible benefits of and obstacles to this approach are delineated.METHODS:One approach to overcoming the poor outcomes associated with conventional glioma therapies involves the replacement of tumor suppressor genes that are fundamental to glioma development. The p53 gene is one of the most frequently mutated genes in human gliomas, and loss of p53 function is critical to the development of glial neoplasms. Consequently, replacement of the p53 gene using viral vectors may be a potential treatment for human gliomasRESULTS:In vitro studies demonstrate that adenovirus-mediated p53 gene transfer into gliomas with mutant p53 results in massive apoptosis. Similarly, transfer of p53 inhibits tumor growth in vivo. In contrast to mutant p53 gliomas, wild-type p53 glioma cells are resistant to the apoptotic effects of p53 transfer, but this resistance can be overcome by the addition of deoxyribonucleic acid-damaging agents such as ionizing radiation or chemotherapy. The main obstacle to p53 gene therapy involves the limitations associated with current modes of deliveryCONCLUSION:Preclinical data strongly support the use of p53 gene transfer as a potential treatment for human gliomas.

Journal

NeurosurgeryOxford University Press

Published: Nov 1, 1999

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off